Clarion

Clarion successfully expands its AI communication platform beyond initial customers, securing major contracts with additional health systems and insurers by demonstrating significant ROI in reducing administrative costs and improving patient engagement. Proprietary healthcare-specific data and strong integrations create a defensible moat, pushing revenue to $50M+ by 2028 and justifying a $280M+ valuation at exit, a 4x return on current valuation.

Clarion continues to grow steadily within its niche, maintaining its customer base and adding new, smaller clients. While the core product performs well, competitive pressure from incumbents and other AI solutions limits aggressive market share capture and pricing power. Revenue reaches $20M by 2028, leading to an acquisition at a $105M valuation, a modest 1.5x return.

Dominant healthcare IT incumbents like Epic or Cerner, or large AI labs, integrate advanced conversational AI features directly into their platforms, commoditizing Clarion's offering. Regulatory hurdles or slower-than-expected adoption by healthcare providers further stifle growth. Revenue stalls, leading to a down round or distressed acquisition at a $14M valuation, resulting in an 80% loss of common stock value.